妊娠期玻璃体腔注射抗血管内皮生长因子药物的安全性研究进展

The progress of research on the safety of intravitreal injection of anti-VEGF drugs during pregnancy

尽管视网膜疾病治疗进入抗血管内皮生长因子(VEGF)时代,但是对于妊娠合并糖尿病视网膜病变、视网膜静脉阻塞及黄斑水肿等抗VEGF药物治疗的安全性仍有疑虑。目前有限的临床病例报道暂未发现玻璃体腔注射抗VEGF药物对妊娠期母亲及胎儿的严重不良影响。但动物实验发现在妊娠早期及中期玻璃体腔注射抗VEGF药物,可导致胎鼠发育迟缓及畸形。妊娠期玻璃体腔注射抗VEGF药物的安全性仍不能确定,需要进一步研究。根据现有的临床报道,无意中在妊娠期玻璃体腔注射抗VEGF药物,一般不会导致严重后果,但需严密观察。目前仍不建议在妊娠期玻璃体腔注射抗VEGF药物。

Although the treatment of retinal diseases has entered the era of anti-vascular endothelial growth factor(VEGF),there are still some doubts about the safety of anti-VEGF treatment fordiabetic retinopathy,retinal vein occlusion and macular edema during pregnancy.At present,limited clinical case report shave told no serious adverse effects of intravitreal injection of anti-VEGF drugs on the mothers and fetuses during pregnancy.However,animal experiments have found that intravitreal injection of anti-VEGF drugs in early and middle pregnancy can lead to developmental retardation and deformity of fetal rats.The safety of intravitreal injection of anti-VEGF drugs during pregnancy is still uncertain and needs further study.According to the existing clinical reports,inadvertent intravitreal injection of anti-VEGF drugs during pregnancy generally does not lead to serious consequences,but it still needs close observation.Intravitreal injection of anti-VEGF drugs during pregnancy is still not recommended at present.